{"ModuleTitle": "Company Description", "CompanyName": "Ironwood Pharmaceuticals, Inc.", "Symbol": "IRWD", "Address": "100 SUMMER STREET, SUITE 2300, BOSTON, Massachusetts, 02110, United States of America", "Phone": "617-621-7722", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "We are a gastrointestinal, or GI, healthcare company dedicated to advancing the\r\ntreatment of GI diseases and redefining the standard of care for millions of GI\r\npatients. We are focused on the development and commercialization of innovative\r\nGI product opportunities in areas of large unmet need, leveraging our\r\ndemonstrated expertise and capabilities in GI diseases.\r\n\r\nLINZESS\u00ae (linaclotide), our commercial product, is the first product approved by\r\nthe United States Food and Drug Administration, or U.S. FDA, in a class of GI\r\nmedicines called guanylate cyclase type C, or GC-C, agonists, and is indicated\r\nfor adult men and women suffering from irritable bowel syndrome with\r\nconstipation, or IBS-C, or chronic idiopathic constipation, or CIC. LINZESS is\r\navailable to adult men and women suffering from IBS-C or CIC in the United\r\nStates, or the U.S., and Mexico and to adult men and women suffering from IBS-C\r\nin Japan and China.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f02%2f13%2f0001558370-20-000779.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "Gina R. Consylman", "title": "Chief Financial Officer & Senior Vice President"}, {"name": "Jason Rickard", "title": "Chief Operating Officer & Senior Vice President"}, {"name": "Mark Mallon", "title": "Chief Executive Officer & Director"}, {"name": "Michael Shetzline", "title": "Chief Medical Officer & Senior Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}